GLP-1 Risk Assessment Calculator: Evaluate Safety, Side Effects, and Metabolic Risk

A GLP-1 risk assessment calculator is a screening tool that evaluates your likelihood of experiencing adverse effects from GLP-1 receptor agonist medications like semaglutide and tirzepatide. It analyzes personal health data, medication selection, dietary habits, and clinical history to generate a numerical risk score between 0 and 100, categorized into low, moderate, high, or very high risk tiers.

The calculator evaluates over 20 individual inputs across six categories: personal baseline data (height, weight, age, sex, BMI), GLP-1 medication selection and treatment duration, hard-stop contraindications (MTC history, MEN2, drug hypersensitivity), major cautions (pregnancy, pancreatitis, gallbladder disease, gastroparesis, kidney disease), weight loss velocity and dietary patterns, and ten weighted clinical risk factors including triglyceride levels, liver disease, tobacco use, and chronic kidney disease staging.

GLP-1 receptor agonists carry several documented risks beyond common gastrointestinal symptoms. Biliary events including gallstones and cholecystitis occur at an elevated rate (RR 1.52 based on meta-analysis of 76 randomized controlled trials), with the risk being significantly higher when GLP-1 medications are used for weight loss (RR 2.29) compared to diabetes management (RR 1.27). Acute pancreatitis risk is also modestly elevated (RR 1.31). Additional concerns include delayed gastric emptying, potential interactions with oral contraceptives, and hypoglycemia risk when combined with insulin or sulfonylureas.

GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and anyone with a known serious hypersensitivity to their selected GLP-1 agent. Major cautions apply to individuals who are pregnant or planning conception (discontinuation is required at least 2 months before planned conception for semaglutide and tirzepatide), those with active or prior pancreatitis, gallbladder disease, severe gastroparesis, or significant kidney impairment.

Yes. Dietary patterns influence biliary complication risk during GLP-1 therapy. Very low fat and low fat diets (under 20% of calories from fat) are associated with lower biliary risk. Balanced diets (20–35% fat) carry moderate risk. High fat diets exceeding 35% of calories from fat are associated with higher risk. Ketogenic diets carry moderate biliary risk primarily due to the rapid weight loss they often produce rather than the macronutrient ratio itself. Intermittent fasting also carries moderate risk because extended fasting windows reduce meal frequency, which decreases gallbladder contraction and may promote bile stasis.

Rapid weight loss is one of the strongest modifiable risk factors for gallbladder complications during GLP-1 therapy. Peak biliary event risk occurs between 6 and 12 months of treatment, coinciding with the most aggressive weight loss phase. Slower titration targeting less than 1 kilogram per week is associated with lower event rates. The calculator evaluates both your weekly weight loss rate and total weight loss percentage to factor this into your overall score.

The calculator includes current FDA-approved GLP-1 receptor agonists and GLP-1/GIP dual agonists. Medication data is current as of March 2026 and includes recent approvals such as Wegovy HD 7.2 mg and Oral Wegovy 25 mg daily. Each agent is evaluated within the context of your selected indication (weight loss, Type 2 diabetes, or both) because risk profiles differ substantially between indications.

The calculator assigns a score from 0 to 100 across four tiers. Low risk (0–24) indicates routine monitoring is generally appropriate with standard follow-up. Moderate risk (25–44) suggests enhanced surveillance with more frequent monitoring during early treatment. High risk (45–64) indicates gastrointestinal consultation should be considered before or during therapy. Very high risk (65–100) means specialist evaluation is strongly recommended before initiating GLP-1 treatment. These tiers are calibrated against safety data from randomized controlled trials and observational cohort studies.

No. GLP-1 receptor agonists should not be used during pregnancy, while trying to conceive, or while breastfeeding. FDA labeling for semaglutide and tirzepatide requires discontinuation at least 2 months before planned conception. If pregnancy occurs during treatment, the medication should be stopped immediately and a physician consulted. The calculator flags this as a major caution and factors it into the risk assessment.

GLP-1 receptor agonists have notable interactions with several medication classes. Combining them with insulin or sulfonylureas increases hypoglycemia risk and may require dose adjustment. GLP-1 medications can also reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying — backup contraception should be considered during initiation and dose escalation. Individuals scheduled for surgery or procedures requiring anesthesia within 30 days should also disclose GLP-1 use, as delayed gastric emptying may increase aspiration risk.

The risk scoring model integrates data from multiple high-quality sources: a meta-analysis of 76 randomized controlled trials examining GLP-1 receptor agonists and biliary events, pooled analyses of acute pancreatitis incidence across GLP-1 trials, gastrointestinal adverse event data published in BMJ and JAMA, the FDA Adverse Event Reporting System (FAERS) database, and real-world pharmacovigilance data. Risk ratios and confidence intervals used in the scoring algorithm are drawn directly from these published datasets.

Most GLP-1 resources focus on efficacy, how much weight you might lose or how much your A1C could drop. This calculator focuses exclusively on the risk side of the equation. It combines contraindication screening, medication-specific biliary risk ratios, dietary pattern analysis, weight loss velocity assessment, and ten weighted clinical risk factors into a single composite score. The tool also provides contextual explanations for each risk factor, citing the specific research behind each data point.